nature portfolio

Peer Review File

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials



Open Access This file is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to

the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. In the cases where the authors are anonymous, such as is the case for the reports of anonymous peer reviewers, author attribution should be to 'Anonymous Referee' followed by a clear attribution to the source work. The images or other third party material in this file are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Editorial Note: this manuscript has been previously reviewed at another journal that is not operating a transparent peer review scheme. This document only contains reviewer comments and rebuttal letters for versions considered at *Nature Communications*.

REVIEWERS' COMMENTS

Reviewer #1 (Remarks to the Author):

The authors state the DTH model was used as a proof-of-concept for T cell-mediated disease. But AD is likely less T cell-mediated than PsO, yet greater therapeutic effect seen in AD. If you want to keep DTH in, then please clearly state the rationale for using it. Otherwise, it does not make a lot of sense.

Related to the above, the lack of strong effect on psoriasis could be unrelated to sample size. It could be biological as well. That should be considered in the discussion.

Reviewer #3 (Remarks to the Author):

The authors have made significant efforts to address previous critiques. I have no further concerns.